Table 4.
Antibiotic consumption
| Pre-intervention period (n = 56) | Intervention period (n = 57) | p value | |
|---|---|---|---|
| DOT/1000 hospital days, n | 860 | 648 | |
| DDD/1000 hospital days, n | 1216 | 946 | |
| Overall antibiotic DOT | 28 (20.75–40) | 20 (10–32) | 0.006 |
| LOT | 21 (14–24.25) | 15 (8–23) | 0.006 |
| Antibiotic-free days | 0 (0–0) | 2 (0–8) | < 0.001 |
| Aminoglycosides, n (%) | 20 (36) | 16 (28) | |
| DOT | 1 (1–1) | 1 (1–1) | 0.553 |
| Carbapenems, n (%) | 26 (46) | 20 (35) | |
| DOT | 9 (6.25–15.25) | 5.5 (4–8) | 0.017 |
| Piperacillin-tazobactam, n (%) | 55 (98) | 49 (86) | |
| DOT | 14 (8–21.5) | 10 (6–17) | 0.084 |
| Cefepime, n (%) | 4 (7) | 20 (35) | |
| DOT | 6.5 (5–10.5) | 7.5 (4–10) | 0.953 |
| Piperacillin-tazobactam/Cefepime/Aztreonam, n (%) | 56 (100) | 56 (98) | |
| DOT | 14.5 (8–22) | 12.5 (8–20) | 0.61 |
| Quinolones, n (%) | 5 (9) | 5 (9) | |
| DOT | 3 (2–8) | 4 (2–8) | 0.733 |
| Anti-resistant Gram-positive agents, n (%) | 36 (64) | 36 (63) | |
| DOT | 11.5 (7–18) | 8 (4–12) | 0.017 |
Data are presented as median (interquartile range) unless otherwise indicated
DOT and LOT are expressed in days
Anti-resistant Gram-positive agents include glycopeptides, lipopeptides and oxazolidinones
Abbreviations: DDD: Defined daily dose; DOT: Days of therapy; LOT: Length of therapy